NCT02285179
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Suspended
Phase 1
Drug Category: Misc Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: The patient has untreated, symptomatic, or progressive brain metastases
https://ClinicalTrials.gov/show/NCT02285179